U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment.

"data availability statement de-identified data will be made available in the harvard dataverse upon publication. data availability statement de-identified data will be made available in the harvard dataverse"

"COMPETING INTERESTS BH is an employee of Pfizer. SMG has received support from Gilead and Cepheid for her research. VCM has received investigator‐initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV. The other authors declare that they have no competing interests directly relevant to the content of this article."

"FUNDING Financial support for this study was provided by National Institutes of Health (NIH) grant R01 MH121424, the University of Washington/Fred Hutch Center for AIDS Research (P30 AI027757) and the Emory University Center for AIDS Research (P30AI050409). SMG and JMS were also supported by the University of Washington Behavioral Research Center for HIV (BIRCH), an NIMH‐funded programme (P30 MH123248). RJYH and ACC are funded in part by NIH grants UM1 AI120176; AI 148055; AI149665; and UNITAID 2020‐39‐GLAD. The funding agreements ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the report. This project also utilized REDCap electronic data capture, which is supported at the University of Washington by grants UL1 TR002319, KL2 TR002317 and TL1 TR002318 from NCATS/NIH."